Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARTV

Artiva Biotherapeutics Inc

Sep 04 • 04:00PM ET

11.38

Dollar change +0.37
Percentage change 3.36	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	50.80%	Shs Outstand	17.58M	Perf Week	6.55%
Market Cap	276.42M	Forward P/E	-	EPS next Y	-	Insider Trans	111.43%	Shs Float	11.95M	Perf Month	2.52%
Income	-	PEG	-	EPS next Q	-0.83	Inst Own	45.73%	Short Float	0.47%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.44	Perf Half Y	-
Book/sh	-234.70	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf Year	-
Cash/sh	1.92	P/C	5.94	EPS next 5Y	-	ROE	-	52W Range	9.71 - 16.00	Perf YTD	-5.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.82%	ROI	-	52W High	-28.87%	Beta	-
Dividend TTM	-	Quick Ratio	4.59	Sales past 5Y	181.38%	Gross Margin	-	52W Low	17.20%	ATR (14)	0.77
Dividend Ex-Date	-	Current Ratio	4.59	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	52.65	Volatility	8.25% 6.18%
Employees	77	Debt/Eq	0.62	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.25
Option/Short	No / Yes	LT Debt/Eq	0.47	EPS Q/Q	-3282.42%	Payout	-	Rel Volume	0.51	Prev Close	11.01
Sales Surprise	-100.00%	EPS Surprise	-1579.39%	Sales Q/Q	-100.00%	Earnings	Aug 29 AMC	Avg Volume	128.85K	Price	11.38
SMA20	4.22%	SMA50	1.27%	SMA200	1.27%	Trades		Volume	66,315	Change	3.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '24	Buy	12.00	8,333,333	99,999,996	8,693,579	Jul 24 04:27 PM
5AM Partners VI, LLC	10% Owner	Jul 22 '24	Buy	12.00	833,333	9,999,996	1,182,054	Jul 24 04:15 PM
venBio Global Strategic Fund I	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,936,637	Jul 22 08:26 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	1,666,666	19,999,992	3,306,900	Jul 22 08:25 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,260,512	Jul 22 08:25 PM
Huh Yong-Jun	Director	Jul 22 '24	Buy	12.00	2,083,332	24,999,984	3,306,900	Jul 22 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTV

Artiva Biotherapeutics Inc

Upgrade your FINVIZ experience